RA Medical Systems (NYSE:RMED) issued its earnings results on Friday. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.80), MarketWatch Earnings reports. The business had revenue of $1.91 million for the quarter, compared to analyst estimates of $2.08 million.
Shares of NYSE RMED opened at $1.27 on Friday. The company has a current ratio of 11.89, a quick ratio of 11.45 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average is $1.45 and its two-hundred day moving average is $2.36. RA Medical Systems has a 52-week low of $1.06 and a 52-week high of $10.43.
A number of brokerages have issued reports on RMED. Piper Jaffray Companies cut shares of RA Medical Systems from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $9.00 to $1.50 in a report on Tuesday, August 13th. Cantor Fitzgerald cut shares of RA Medical Systems from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $10.00 to $2.00 in a report on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. RA Medical Systems presently has an average rating of “Hold” and a consensus price target of $6.38.
Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
Featured Story: Return On Assets
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.